NEM0T0, R., SHINDO, M., MOnI, H., ABE, R. and KATO, T. Intravesical Chemotherapy of Urinary Bladder Tumor in Rabbit by Ferromagnetic Mitomycin C. Tohoku J. exp. Med., 1983, 139 (3), [315] [316] [317] [318] [319] [320] Considering the necessity of selective toxicity in cancer chemotherapy, an advantageous means of controlling the anticancer agent in the urinary bladder was facilitated by microencapsulation of the drug and ferrite particles.
Pharmacokinetic analysis of intravesical instillation chemotherapy in rabbits proved that magnetic control of ferromagnetic microencapsulated mitomycin C (MMC) remarkably enhanced MMC absorption into the urinary bladder wall. Moreover, malignant bladder tumors in rabbits were successfully treated with this method. --intravesical chemotherapy; magnetic control; bladder tumor; rabbits Intravesical administration of antineoplastic agents has been the subject of urological cancer chemotherapy (Soloway 1980) . It has been restricted to the case of superficial bladder cancer in this type of therapy. The drug, such as mitomycin C (MMC), showing lower absorption from the bladder mucosal layer would make it an ideal agent for topical use (Soloway et al. 1981 ). However, this type of drug is inappropriate in the presence of solid infiltrating bladder cancer, because of its low permeability into the bladder wall through mucosal layer.
A comprehensive review of the literature concerning the application of intravesical instillation for increasing permeability of the drug disclosed numerous descriptions of technique but failed to demonstrate its effectiveness. We present here new means of providing selective toxicity and high permeability to the drug in urinary bladder using magnetic control of microencapsulated MMC.
MATERIALS AND METHODS
Ferromagnetic mitomycin C microcapsules (FM-MMC-m.c.)
The preparation and properties of the FM-MMC-m.c. have been reported previously (Kato et al. 1979 ). Briefly, FM-MMC-m.c. consisted of 50 per cent (w/w) MMC as the core, and 34 per cent ethylcellulose and 16% of zinc ferrite (Zn20Fe80. Fe203) as the shell with a particle size of 307.9+34.5 ym. Release rate of MMC from FM-MMC-m.c. was 45.8±4.3% at 1 hr incubation in 37°C saline stirring at 25 rpm and 78.1+5.6% at 6 hr Received for publication, June 8, 1982. 315 incubation. Placebo ferromagnetic microcapsules (FM-me.) containing lactose in lieu of MMC as the core were also prepared in the same manner.
Permeability of the bladder mucosa to MMC Twelve rabbits (Japanese White) of approximately 3 kg were anesthetized with pentobarbital (25 mg per kg of body weight). A samarium magnet (3,500 Oe/cm, 1 cm in diameter) was fixed to the external bladder wall with surgical adhesive paste by laparotomy. The drugs under test were diluted in 6 ml of 0.9% NaCI solution (saline) and instilled into the bladder lumen by intravesical catheterization. All experiments were carried out under bilateral ureterostomy.
Rabbtis were divided into three experimental groups : Group 1 (four rabbits) ; 6 mg of nonencapsulated MMC (Mitomycin S, Kyowa Hakko Kogyo Co. Ltd., Japan) ; Group 2 (four rabbits) ; 6 mg of nonencapsulated MMC and 6 mg of placebo FM-me. ; Group 3 (four rabbits) 6 mg of FM-MMC-m.c.
Blood samples were obtained from the inferior vena cava at the determined intervals. Extirpation of the urinary bladder was done 3 hr after drug instillation. Bioassay for MMC in the serum and tissue homogenate was performed by the agar diffusion method using Escherichia coli B-ATCC 11303.
Bladder tumor in rabbit A model of malignant urinary bladder tumor in rabbits using V2 carcinoma was used in this study (Nemoto et al. 1981a) . A fresh V2 carcinoma was aseptically excised from the hind limb of rabbit and all fibrous tissue was trimmed off for the preparation of singlecell suspension. After mincing with scissors, Hanks' balanced salt solution was added to the tumor pulp and the pulp was put through a gauze filter into a sterile dish. Viable tumor cell number of the cell suspension was counted by microscopic study and tumor cell suspension in 0.3 ml of solution was prepared for injection. Mitomycin C induced marked cytotoxic effects on the V2 carcinoma cells treated for 2 hr in vitro, with the 90% inhibition dose of 1.Oyg/ml (Nemoto et al. 1981b ).
I ntravesical chemotherapy
Twenty-four rabbits anesthetized with pentobarbital (25 mg/kg) were prepared to make cystostomy for the intravesical instillation. After exposing the urinary bladder, a catheter (2 mm in external diameter, ATOM Co. Ltd., Japan) was inserted into the bladder lumen near the neck and fixed at the bladder wall by cutgut suture. The catheter was subcutaneously guided to the back and the outlet was fixed through the skin. After 106 V2 carcinoma cells were transplanted into the urinary bladder wall far away from the catheter, a samarium magnet was fixed to the external bladder wall. Three days after the inoculation of V2 carcinoma cells, instillation of the tested drug was started through the catheter.
In this study the animals were divided into three experimental groups: Group 1, twelve rabbits were instilled with 6 ml saline a day for ten days as a control; Group 2, four rabbits were instilled with 6 mg nonencapsulated MMC a day for ten days; Group 3, four rabbits were treated by a single injection of 6 mg FM-MMC-m.c.; Group 4, four rabbits were instilled with 6 mg of FM-MMC-m.c. a day for five days. In Group 2, the instilled drug was kept in urinary bladder for over 1 hr a day. Experiment I (Groups 1 and 2) and Experiment II (Groups 1, 3, 4) were carried out separately.
Twenty days after the inoculation of V2 carcinoma cells the rabbits were sacrificed to check for tumor size. The average size of the tumor was calculated using the formula, length x width mm2 (mean±s.E.), because this malignant urinary bladder tumor in rabbits tends to grow in a two dimensional pattern (Nemoto et al. 1981a ). only one sample. In Group 3 urinary bladder wall around the area of samarium magnet also indicated a lower concentration of MMC. Table 2 shows the MMC levels in the circulating blood in each experimental group. Blood MMC levels of Group 3 (FM-MMC-m.c.) were significantly higher than those of Group 1 and Group 2 (nonencapsulated MMC group with or without placebo FM-m.c.).
RESULTS

Absorption of MMC
Antitumor effect on bladder tumor in rabbit Table 1 
DISCUSSION
Previously we reported that MMC can be microencapsulated with ethylcellulose and that this dosage form releases the encased drug for a prolonged period of time in experimental study as well as in clinical investigation (Kato et al. 1980 Nemoto and Kato 1981b) . Considering the necessity of selective toxicity in cancer chemotherapy, an advantageous means of controlling the microcapsules in luminal spaces such as the urinary bladder may be facilitated in combination with medicine and technology. We presented here the antitumor effect of ferromagnetic MMC microcapsules (FM-MMC-m.c.) on bladder tumor in rabbit, which was conducted by an extravesical magnetic field.
In this study, the data consistently showed that selective toxicity and high permeability of bladder mucosa to MMC were controlled by microcapsulation and magnetic conduction.. Urinary bladder wall from the area where FM-MMC-m.c. was conducted always retained higher concentrations of MMC as bladder tumors in rabbits were successfully treated with this method. Single injections of FM-MMC-m.c. (total dosage of MMC; 6 mg) significantly (p<0.025) reduced the growth of bladder tumor and several injections (total dosage of MMC; 30 mg) of the drug showed remarkable antitumor effect (p<0.001), as compared with the injection of nonencapsulated MMC which showed no antitumor effect on bladder tumors in rabbits with a total dosage of 60 mg. High permeability of bladder mucosa to MMC increased the blood levels of MMC, but no lethal damage was seen in any rabbit.
In view of our findings, it could be concluded that microencapsulation of antineoplastic agent with ferrite and its magnetic conduction provide selective toxicity and high permeability to bladder mucosa in Intravesical administration. The results suggest the possibility that FM-MMC-m.c. are conducted into an infiltrative cancerous lesion in the urinary bladder, facilitating an intensive intravesical chemotherapy. We are currently investigating the clinical application of FM-MMC-m.c, in urinary bladder cancer. Effect of mitomycin C on superficial bladder cancer. J. Urol.,125, 646-650.
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